Robert E Miller Net Worth

The estimated Net Worth of Robert E Miller is at least $61.7 Thousand dollars as of 12 March 2018. Robert Miller owns over 2,400 units of Sonoma Pharmaceuticals stock worth over $61,698 and over the last 8 years Robert sold SNOA stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Robert Miller SNOA stock SEC Form 4 insiders trading

Robert has made over 8 trades of the Sonoma Pharmaceuticals stock since 2016, according to the Form 4 filled with the SEC. Most recently Robert bought 2,400 units of SNOA stock worth $9,744 on 12 March 2018.

The largest trade Robert's ever made was buying 5,000 units of Sonoma Pharmaceuticals stock on 8 December 2016 worth over $24,300. On average, Robert trades about 1,467 units every 38 days since 2016. As of 12 March 2018 Robert still owns at least 18,868 units of Sonoma Pharmaceuticals stock.

You can see the complete history of Robert Miller stock trades at the bottom of the page.

What's Robert Miller's mailing address?

Robert's mailing address filed with the SEC is C/O SONOMA PHARMACEUTICALS, INC., 1129 N. MCDOWELL BLVD., PETALUMA, CA, 94954.

Insiders trading at Sonoma Pharmaceuticals

Over the last 8 years, insiders at Sonoma Pharmaceuticals have traded over $0 worth of Sonoma Pharmaceuticals stock and bought 25,155 units worth $125,359 . The most active insiders traders include Frederick J Sandford, Sharon Barbari, and Robert E Miller. On average, Sonoma Pharmaceuticals executives and independent directors trade stock every 27 days with the average trade being worth of $4,840. The most recent stock trade was executed by Robert E Miller on 12 March 2018, trading 2,400 units of SNOA stock currently worth $9,744.

What does Sonoma Pharmaceuticals do?

sonoma pharmaceuticals, inc., develops and produces stabilized hypochlorous acid (hocl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the united states and internationally. the company offers epicyn, an antimicrobial facial cleanser; levicyn, a hypochlorous acid (hocl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; sebuderm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and ceramax, a lipogrid based skin barrier cream for management of dry itchy skin, minor skin irritations, rashes, and inflammation caused by various skin conditions, as well as loyon for the management of skin scal

Complete history of Robert Miller stock trades at Sonoma Pharmaceuticals

Sonoma Pharmaceuticals executives and stock owners

Sonoma Pharmaceuticals executives and other stock owners filed with the SEC include:

• Bruce Thornton,
  Chief Operating Officer, Secretary
• Bruce Thornton,
  COO & Corp. Sec.
• Amy M. Trombly,
  CEO & Pres
• Amy Trombly,
  Chief Executive Officer
• Jerome Dvonch,
  Chief Financial Officer
• Philippe Weigerstorfer,
  Independent Director
• Jay Birnbaum,
  Independent Director
• Sharon Barbari,
  Independent Director
• Jerry McLaughlin,
  Lead Independent Director
• Jerry Dvonch,
  Chief Financial Officer
• Victoria Covel,
  Assistant Controller
• Dr. Robert Northey,
  Exec. VP of R&D
• Russell Joseph Harrison,
  Director
• John Mclaughlin,
  Director
• Marc Umscheid,
  Chief Strategy/Mkt Officer
• Robert Grant Edwards,
  Chief Financial Officer
• Poggetto John Dal,
  Controller
• Robert Allen Northey,
  Exec. VP of Res & Development
• James J Schutz,
  
• Robert E Miller,
  
• Frederick J Sandford,
  CEO and Interim CFO
• Chad Norman White,
  Chief Financial Officer
• Jerome J Dvonch,
  Chief Financial Officer